{"filing":{"accession_number":"0001193125-26-273405","cik":"0001540171","ticker":"AVLN","company_name":"Avalyn Pharma Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"ck0001540171-20260617.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526273405/ck0001540171-20260617.htm"},"events":[{"id":11449,"run_id":10052,"accession_number":"0001193125-26-273405","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M\u0026A, executive changes, or other specifically enumerated event types.","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8040,"accession_number":"0001193125-26-273405","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M\u0026A, executive changes, or other specifically enumerated event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:04:08.531473+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8040,"accession_number":"0001193125-26-273405","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M\u0026A, executive changes, or other specifically enumerated event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T12:04:08.531473+00:00","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-06-17"}]}